Farletuzumab

Farletuzumab (MORAb-003) is a humanized monoclonal antibody^[1] of IgG1/κ^[2] which is being investigated for the treatment of ovarian cancer.^[3][4]

Farletuzumab

Monoclonal antibody
Type	Whole antibody
Source	Humanized
Target	FR-alpha
Clinical data
Routes of administration	Intravenous injection
ATC code	none
Identifiers
CAS Number	896723-44-7 N
ChemSpider	none
UNII	2O09BG0OWA
KEGG	D09343 Y
Chemical and physical data
Formula	C6466H9928N1716O2020S42
Molar mass	145371.06 g·mol−1
NY (what is this?)  (verify)

This drug was developed by Morphotek, Inc.

It is targeted at folate receptor alpha (FRα) which is overexpressed in some cancers such as epithelial ovarian cancer (EOC) and non-small-cell lung carcinoma.^[2]

Mechanism of action

Farletuzumab uses the following mechanisms of action:^[2]

• Antibody-dependent cellular cytotoxicity
• Complement-dependent cytotoxicity
• Inhibition of interaction between FRα and Lyn kinase
• Induces cell death associated with autophagy

Adverse effects

Common adverse effects include hypersensitivity reactions, fever, chills, headache, fatigue, and diarrhea.^[2]

References

1. Statement On A Nonproprietary Name Adopted By The Usan Council - Farletuzumab, American Medical Association.
2. Sato S, Itamochi H (2016-03-07). "Profile of farletuzumab and its potential in the treatment of solid tumors". OncoTargets and Therapy. 9: 1181–8. doi:10.2147/OTT.S98242. PMC 4789847. PMID 27022278.
3. Clinical trial number NCT00738699 for "Phase II Efficacy and Safety Study of MORAb-003 in Platinum-Resistant or Refractory Relapsed Ovarian Cancer" at ClinicalTrials.gov
4. Clinical trial number NCT00849667 for "Phase III Efficacy and Safety of MORAb-003 in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse" at ClinicalTrials.gov